Victory Capital Management
SGMO

Victory Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Victory Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4K Buy
42,040
+4,156
+11% +$1.65K ﹤0.01% 2396
2025
Q4 		$15.9K Buy
37,884
+4,339
+13% +$2.3K ﹤0.01% 2397
2025
Q3 		$22.6K Buy
33,545
+5,215
+18% +$2.81K ﹤0.01% 2390
2025
Q2 		$15.3K Buy
28,330
+4,305
+18% +$2.56K ﹤0.01% 2458
2025
Q1 		$15.8K Sell
24,025
-602
-2% -$637 ﹤0.01% 2442
2024
Q4 		$25.1K Buy
24,627
+848
+4% +$1.55K ﹤0.01% 2432
2024
Q3 		$20.6K Sell
23,779
-321
-1% -$235 ﹤0.01% 2442
2024
Q2 		$8.63K Buy
+24,100
New +$13K ﹤0.01% 2471
2023
Q4 		– Sell
-16,738
Closed -$10K – 2633
2023
Q3 		$10K Buy
16,738
+747
+5% +$800 ﹤0.01% 2486
2023
Q2 		$20.8K Buy
15,991
+1,266
+9% +$1.73K ﹤0.01% 2446
2023
Q1 		$25.9K Sell
14,725
-200
-1% -$571 ﹤0.01% 2492
2022
Q4 		$46.9K Sell
14,925
-6
-0% -$23 ﹤0.01% 2460
2022
Q3 		$73K Sell
14,931
-937
-6% -$4.81K ﹤0.01% 2521
2022
Q2 		$66K Sell
15,868
-29
-0.2% -$125 ﹤0.01% 2520
2022
Q1 		$66K Sell
15,897
-421
-3% -$2.5K ﹤0.01% 2568
2021
Q4 		$122K Sell
16,318
-687
-4% -$5.97K ﹤0.01% 2546
2021
Q3 		$153K Sell
17,005
-452
-3% -$4.47K ﹤0.01% 2572
2021
Q2 		$209K Sell
17,457
-464
-3% -$5.25K ﹤0.01% 2519
2021
Q1 		$225K Sell
17,921
-324
-2% -$4.37K ﹤0.01% 2500
2020
Q4 		$285K Buy
18,245
+1,211
+7% +$14.2K ﹤0.01% 2295
2020
Q3 		$161K Sell
17,034
-1,205
-7% -$13K ﹤0.01% 2309
2020
Q2 		$163K Sell
18,239
-19,143
-51% -$178K ﹤0.01% 2326
2020
Q1 		$238K Buy
37,382
+14,778
+65% +$110K ﹤0.01% 2289
2019
Q4 		$189K Buy
22,604
+3,078
+16% +$28.3K ﹤0.01% 2324
2019
Q3 		$177K Buy
+19,526
New +$219K ﹤0.01% 2256

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Victory Capital Management's SGMO Position: Q1 2026 in Review

Victory Capital Management increased its SANGAMO THERAPEUTICS INC (SGMO) stake by 11% in Q1 2026, buying an estimated $1.65K and bringing the position to 42,040 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2396.

Victory Capital Management first reported a position in SGMO in Q3 2019 and has held it in 25 quarters since. The position peaked at $285K in Q4 2020. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • Victory Capital Management held 42,040 shares of SANGAMO THERAPEUTICS INC worth $10.4K as of Q1 2026.
  • Victory Capital Management bought 4,156 SANGAMO THERAPEUTICS INC shares in Q1 2026, an estimated $1.65K.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2396 holding.
  • Victory Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q3 2019 and has held it in 25 quarters since.
  • Victory Capital Management's SANGAMO THERAPEUTICS INC position peaked at $285K in Q4 2020.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.